New leukemia drug asciminib tracked in real-world saudi study
NCT ID NCT06684964
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study follows about 40 adults in Saudi Arabia with chronic-phase chronic myeloid leukemia (CML) who have already tried two other targeted therapies. Researchers will track how well asciminib controls the cancer, its side effects, and how consistently patients take the medication. The goal is to see how the drug performs in everyday medical practice, not in a controlled lab setting.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC MYELOGENOUS LEUKEMIA IN CHRONIC PHASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
Novartis Investigative Site
RECRUITINGDammam, 15215, Saudi Arabia
-
Novartis Investigative Site
RECRUITINGJeddah, 21423, Saudi Arabia
-
Novartis Investigative Site
RECRUITINGRiyadh, 11211, Saudi Arabia
-
Novartis Investigative Site
RECRUITINGRiyadh, 11426, Saudi Arabia